Biotech

Gilead Exercises its Option to License Nurix’s NX-0479 for Cancer

Gilead Exercises its Option to License Nurix’s NX-0479 for Cancer

Shots: Nurix will receive $20M in option exercise fees and receive an additional ~...

Alnylam Expands its Collaboration with Medison Pharma to Commercialize RNAi Therapies

Alnylam Expands its Collaboration with Medison Pharma to Commercialize RNAi Therapies

Shots: The companies have decided to expand their existing collaboration for RNA i...

Image